Bacillus anthracis Antibody (BAL0106)

Product Discontinued

Bacillus anthracis Antibody (BAL0106) Summary

• Immunogen: Highly purified lethal factor antigen of Bacillus anthracis.
• Specificity: Lethal factor antigen of Bacillus anthracis
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Sandwich ELISA 1:100-1:2000
• Application Notes: Best recommended pairs (capture-detection): NB110-2501 - NB110-2500

Reactivity Notes

Bacteria.

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: PBS
• Preservative: 0.09% Sodium Azide
• Purity: Protein G purified

Alternate Names for Bacillus anthracis Antibody (BAL0106)

• Anthrax lethal factor
• Anthrax lethal toxin endopeptidase component
• Anthrax LF
• B.anthracis lethal factor
• bacillus anthracis lethal factor
• Lef
• LF

Background

The protease enzyme Lethal Factor (LF) is one of the three proteins (LF, EF & PA) composing the anthrax toxin produced by Bacillus anthracis, a bacteria which can infect many mammalian species and that may be fatal. LF is not toxic by itself, but when associated with Protective Antigen (PA), can then gain entry to cells. Once inside the cell, LF then cleaves the N terminal of most dual specificity mitogen activated protein kinase kinases (MAPKKs or MAP2Ks) (except for MAP2K5). Cleavage invariably occurs within the N terminal proline rich region preceding the kinase domain, thus disrupting a sequence involved in directing specific protein protein interactions necessary for the assembly of signaling complexes. There may be other cytosolic targets of LF involved in cytotoxicity. The proteasome may mediate a toxic process initiated by LF in the cell cytosol involving degradation of unidentified molecules that are essential for macrophage homeostasis. This is an early step in LF intoxication, but it is downstream of the cleavage by LF of MEK1 or other putative substrates.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.